Ascendis Pharma A/S (ASND)
120.97
-1.83
(-1.49%)
USD |
NASDAQ |
May 17, 16:00
120.97
0.00 (0.00%)
After-Hours: 20:00
Ascendis Pharma Enterprise Value: 7.294B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 7.294B |
| May 16, 2024 | 7.390B |
| May 15, 2024 | 7.461B |
| May 14, 2024 | 7.443B |
| May 13, 2024 | 7.851B |
| May 10, 2024 | 7.932B |
| May 09, 2024 | 7.914B |
| May 08, 2024 | 7.959B |
| May 07, 2024 | 8.075B |
| May 06, 2024 | 7.963B |
| May 03, 2024 | 8.144B |
| May 02, 2024 | 8.365B |
| May 01, 2024 | 8.360B |
| April 30, 2024 | 8.214B |
| April 29, 2024 | 8.311B |
| April 26, 2024 | 8.071B |
| April 25, 2024 | 8.129B |
| April 24, 2024 | 8.483B |
| April 23, 2024 | 8.576B |
| April 22, 2024 | 8.422B |
| April 19, 2024 | 8.312B |
| April 18, 2024 | 8.353B |
| April 17, 2024 | 8.426B |
| April 16, 2024 | 8.388B |
| April 15, 2024 | 8.599B |
| Date | Value |
|---|---|
| April 12, 2024 | 8.645B |
| April 11, 2024 | 8.928B |
| April 10, 2024 | 9.015B |
| April 09, 2024 | 9.077B |
| April 08, 2024 | 8.805B |
| April 05, 2024 | 8.862B |
| April 04, 2024 | 8.736B |
| April 03, 2024 | 8.840B |
| April 02, 2024 | 8.659B |
| April 01, 2024 | 8.981B |
| March 31, 2024 | 8.935B |
| March 28, 2024 | 8.720B |
| March 27, 2024 | 8.565B |
| March 26, 2024 | 8.651B |
| March 25, 2024 | 8.340B |
| March 22, 2024 | 8.372B |
| March 21, 2024 | 8.438B |
| March 20, 2024 | 8.327B |
| March 19, 2024 | 8.391B |
| March 18, 2024 | 8.487B |
| March 15, 2024 | 8.580B |
| March 14, 2024 | 8.647B |
| March 13, 2024 | 8.878B |
| March 12, 2024 | 8.869B |
| March 11, 2024 | 8.550B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.265B
Minimum
May 11 2022
9.186B
Maximum
Feb 23 2024
6.092B
Average
6.012B
Median
Enterprise Value Benchmarks
| Evaxion Biotech AS | 22.47M |
| Biodexa Pharmaceuticals Plc | -2.388M |
| TC BioPharm (Holdings) PLC | 0.4733M |
| Genmab A/S | 15.08B |
| NuCana PLC | -14.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -142.33M |
| Revenue (Quarterly) | 104.16M |
| Total Expenses (Quarterly) | 157.54M |
| EPS Diluted (Quarterly) | -2.498 |
| Gross Profit Margin (Quarterly) | 92.11% |
| Profit Margin (Quarterly) | -136.6% |
| Earnings Yield | -7.97% |
| Normalized Earnings Yield | -7.965 |